ETF Holdings Breakdown of CLBT

Stock NameCellebrite DI
TickerCLBT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINIL0011794802

News associated with CLBT

Notable ETF Inflow Detected - SCZ, TIGO, ODD, CLBT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE Small-Cap ETF (Symbol: SCZ) where we have detected an approximate $243.5 million dollar inflow -- that's a 2.6% increase week over - 2025-05-09 14:54:18
NewEdge Advisors LLC Has $86,000 Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)
NewEdge Advisors LLC increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 600.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,910 shares of the company’s stock after purchasing an additional 3,352 shares during the quarter. NewEdge Advisors LLC’s holdings in Cellebrite DI were worth $86,000 as of its most […] - 2025-05-04 08:42:48
Noteworthy ETF Outflows: SCZ, CLBT, ODD, INMD
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE Small-Cap ETF (Symbol: SCZ) where we have detected an approximate $172.9 million dollar outflow -- that's a 1.8% decrease week ove - 2025-05-01 15:46:40
Head to Head Analysis: Cellebrite DI (NASDAQ:CLBT) versus Intellicheck (NYSE:IDN)
Intellicheck (NYSE:IDN – Get Free Report) and Cellebrite DI (NASDAQ:CLBT – Get Free Report) are both industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Analyst Ratings This is a summary of current ratings […] - 2025-04-24 05:28:50
Legal & General Group Plc Purchases 36,949 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)
Legal & General Group Plc boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 30.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 160,223 shares of the company’s stock after buying an additional 36,949 shares during the period. Legal & […] - 2025-04-23 08:21:01
JPMorgan Chase & Co. Has $7.31 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)
JPMorgan Chase & Co. trimmed its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 22.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 331,665 shares of the company’s stock after selling 95,990 shares during the period. JPMorgan Chase & Co.’s holdings in Cellebrite DI were worth $7,307,000 as […] - 2025-04-17 07:27:15
Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Acquired by Sei Investments Co.
Sei Investments Co. increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 43.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 408,043 shares of the company’s stock after buying an additional 124,558 shares during the quarter. […] - 2025-03-31 07:48:59
Noteworthy ETF Inflows: SCZ, ZIM, CLBT, ODD
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE Small-Cap ETF (Symbol: SCZ) where we have detected an approximate $390.8 million dollar inflow -- that's a 4.4% increase week over - 2025-03-24 14:51:29
Cellebrite DI (NASDAQ:CLBT) Receives Buy Rating from Needham & Company LLC
Cellebrite DI (NASDAQ:CLBT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They currently have a $28.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 62.51% from the stock’s […] - 2025-03-12 06:08:56
Principal Financial Group Inc. Sells 334,666 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)
Principal Financial Group Inc. reduced its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 24.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,054,988 shares of the company’s stock after selling 334,666 shares during the quarter. Principal Financial Group Inc.’s […] - 2025-02-24 08:50:55
Cellebrite DI (NASDAQ:CLBT) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Cellebrite DI (NASDAQ:CLBT – Free Report) in a research note released on Friday,Benzinga reports. They currently have a $28.00 price target on the stock. CLBT has been the subject of several other reports. Craig Hallum upped their price target on shares of Cellebrite DI […] - 2025-02-17 08:42:58
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cellebrite DI (NASDAQ:CLBT) Stock
Cellebrite DI (NASDAQ:CLBT – Get Free Report) had its target price hoisted by equities research analysts at JPMorgan Chase & Co. from $24.00 to $28.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of […] - 2025-02-13 08:52:53

CLBT institutional holdings

The following institutional investment holdings of CLBT have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 68,479USD 1,320,275 1.0%
2024-12-10 IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc) 648USD 12,889 0.1%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 257USD 4,955 1.0%
Total =69,384 USD 1,338,119
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.